Loading...

BCRX BIOCRYST PHARMACEUTICALS INC Company Mergers 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2025 8-K

FDA Approval Announcement

Director Retirement

Merger Approval Update

Financial Update

Merger Agreement

Equity Sale Completed

Financial Statements

Stock Purchase Agreement

Clinical Trials

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

On October 1, 2025, BioCryst Pharmaceuticals Inc. completed the sale of its equity interests in BioCryst Ireland for $250 million, as announced previously on June 27, 2025. This transaction includes amended agreements for licensing and supply related to the ORLADEYO® product.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.